Streetbeat News

Analyst Ratings

ICCM

Alliance Global Partners analyst Ben Haynor maintains a 'Buy' rating on Icecure Medical (NASDAQ:ICCM) but lowers the price target from $4.25 to $4.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:17 pm

VRME

Barrington Research analyst Michael Petusky has maintained an 'Outperform' rating on VerifyMe (NASDAQ:VRME) but lowered the price target from $2 to $1.7.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:12 pm

TMC

Wedbush analyst Daniel Ives has reiterated a Neutral rating on TMC Metals (NASDAQ:TMC) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 1:11 pm

LICY

Wedbush analyst Daniel Ives has reiterated an 'Outperform' rating on Li-Cycle Holdings (NYSE:LICY) and maintained a price target of $8.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 1:10 pm

SKY

Wedbush analyst Jay McCanless has reiterated an Outperform rating on Skyline Champion (NYSE:SKY) and maintained a $78 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 1:09 pm

HD

Telsey Advisory Group analyst Joseph Feldman has reiterated a 'Market Perform' rating on Home Depot (NYSE:HD) and maintained a price target of $315.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:08 pm

GETY

Benchmark analyst Mark Zgutowicz maintains a Buy rating on Getty Images Holdings (NYSE:GETY) but lowers the price target from $8 to $7.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 1:08 pm

UGRO

Small Cap Consumer Research analyst Eric Beder has reiterated a 'Buy' rating on Urban-gro (NASDAQ:UGRO) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:07 pm

CSSE

Benchmark analyst Daniel Kurnos has maintained a 'Buy' rating on Chicken Soup for the Soul (NASDAQ:CSSE) but lowered the price target from $12 to $6.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 1:05 pm

ALPN

Wedbush analyst Robert Driscoll maintains an Outperform rating on Alpine Immune Sciences (NASDAQ:ALPN) and raises the price target from $17 to $19.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 1:05 pm